Nurse-and-allergist provocation pathway for penicillin allergy delabelling (PANDA)
Official title: Provocation After Nurse-Directed Assessment (PANDA) Study
Run by The University of Hong Kong · NCT07127835 · Data updated 2026-11-12
This project will try a nurse-and-allergist team approach to remove incorrect penicillin allergy labels in patients treated at participating hospitals, and compare it to the usual allergist-only pathway.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 440 (estimated) |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 4 sites (Hong Kong and 3 other locations) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | August 31, 2027 |
| Study ends | August 31, 2029 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT07127835 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Patients with a documented penicillin allergy who are receiving care at one of the participating Hong Kong hospitals and can provide a complete medication and allergy history.
✕Probably not a fit
Patients unable to provide a full allergy or medication history, those with only emergency or short-term records, or those who recently used steroids or antihistamines likely will not benefit from this delabelling approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
PANDA is an observational comparison of a nurse-allergist collaborative delabelling service versus a traditional allergist-led service for patients with a documented penicillin allergy across three Hong Kong hospitals. Patients are stratified by clinical risk and, where appropriate, undergo nurse-directed history-taking and drug provocation testing with allergist oversight; clinical outcomes, safety events, and quality-of-life measures are recorded. The study collects demographic and clinical data from inpatient and outpatient records and compares resource use and cost-effectiveness between the two care models. Exclusions include patients without a complete medication/allergy history, those with only short-term emergency records, or recent use of steroids or antihistamines that would affect testing.
Why it matters
Potential benefit: If successful, the collaborative pathway could safely remove incorrect penicillin allergy labels faster and at lower cost, increasing appropriate antibiotic options for patients.
How similar studies have gone: Previous programs using risk stratification and direct drug provocation for penicillin delabelling, including nurse-led pathways, have shown good safety and high rates of successful delabelling.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Receiving inpatient or outpatient treatment at a participating hospital during the study period; * Possessing a documented penicillin allergy label; * Underwent penicillin allergy evaluation by the nurse-allergist collaborative approach or the traditional allergist-led approach * Demographic and clinical data required for the study available. Exclusion Criteria: * Patients unable to provide a complete medication history or history of penicillin allergy; * Patients with only emergency or short-term treatment records; * Patients who have taken steroids, antihistamines, or similar medications within the last 3 days.
Where it's running
-
Prince of Wales Hospital
Hong Kong, Hong Kong Recruiting -
Princess Margaret Hospital
Hong Kong, Hong Kong Recruiting -
Queen Elizabeth Hospital
Hong Kong, Hong Kong Recruiting -
Queen Mary Hospital
Hong Kong, Hong Kong Recruiting
Study contacts
- Study coordinator: Elaine Lee
- Email: le446@hku.hk
- Phone: 852 9440 3349
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing for Teicoplanin Allergy Using Patients' Own Blood
This study is testing a new way to check if patients who had a serious allergic reaction to Teicoplanin are really allergic by using their own blood to make the allergy test more accurate.
-
Testing for safe removal of penicillin allergy labels
This study is testing if a new way to check if people with low-risk penicillin allergies can safely take penicillin without needing skin tests.
-
Optimizing allergy testing for cephalosporin antibiotics
This study is testing a new way to diagnose cephalosporin allergies in patients to help them avoid severe allergic reactions.
-
Testing a single versus double dose of amoxicillin for penicillin allergy delabeling
This study tests whether giving one dose of amoxicillin is just as safe and effective as giving two doses for adults who have been labeled as penicillin-allergic but are considered low-risk.
-
Analyzing immune cells in children undergoing anesthesia
This study looks at how immune cells in children aged 2 to 18 react to anesthesia and a specific medication to better understand their immune response and any potential allergies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.